Adverse events with isoniazid preventive therapy: experience from a large trial. by Grant, Alison D et al.
van Halsema, CL; Fielding, KL; Chihota, VN; Russell, EC; Lewis, JJ;
Churchyard, GJ; Grant, AD (2010) Tuberculosis outcomes and drug
susceptibility in individuals exposed to isoniazid preventive therapy
in a high HIV prevalence setting. AIDS (London, England), 24 (7).
pp. 1051-5. ISSN 0269-9370
Downloaded from: http://researchonline.lshtm.ac.uk/3867/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
 
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid 
preventive therapy in a high HIV prevalence setting 
 
Clare L VAN HALSEMA1, Katherine L FIELDING1, Violet N CHIHOTA2, Elizabeth C 
RUSSELL1, James JC LEWIS1, Gavin J CHURCHYARD2, Alison D GRANT1 
 
1London School of Hygiene and Tropical Medicine, London, UK 
2The Aurum Institute, Johannesburg, South Africa 
 
Running head: TB after isoniazid preventive therapy 
Word count:   Abstract: 250    Text: 1817 
 
Corresponding author: 
Dr Clare L van Halsema 
Clinical Research Unit, Department of Infectious and Tropical Diseases 
London School of Hygiene and Tropical Medicine 
Keppel Street, London WC1E 7HT, UK 
e-mail: claretaylor@doctors.org.uk or  clare.vanhalsema@lshtm.ac.uk    
telephone: +44(0) 7538 334647 
fax: +44 (0) 20 7637 4314 
 
Sources of support: Consortium to Respond Effectively to the AIDS and TB Epidemics 
(CREATE; funded by a grant from the Bill and Melinda Gates Foundation); The Colt 
Foundation, UK; Department of Health, UK; Safety in Mines Research Advisory 
Committee, South Africa.  
 
2 
 
 
ABSTRACT 
Objective 
Despite World Health Organization recommendations, concerns about promoting 
resistance have impeded implementation of isoniazid preventive therapy (IPT) for 
tuberculosis. We describe characteristics of tuberculosis in individuals previously 
exposed to IPT as part of “Thibela TB”, a cluster-randomised trial of community-wide IPT 
in gold miners in South Africa. 
Design 
Case series including participants who were dispensed IPT, attended at least one follow-
up visit and were subsequently treated for tuberculosis. 
Methods 
Tuberculosis episodes were detected through surveillance and through follow-up if IPT 
was stopped early. Drug susceptibility data were compared with a) tuberculosis episodes 
detected through surveillance in control clusters (where IPT use was minimal) and b) a 
laboratory substudy of mycobacterial sputum culture from tuberculosis suspects in 
control clusters.  
Results 
Among 126 eligible individuals (125 male, median age 43 years), median time from 
starting IPT to tuberculosis treatment was 316 days (IQR 174-491). 94/126 (75%) were 
first episodes. 89/103 (86%) tested HIV-infected, median CD4 count 196 cells/mm3 
(n=51). 64/108 (59%) with known treatment outcomes were cured or completed 
treatment. Among 71 isolates with drug susceptibility results available, 12.1% (95% CI 
5.0-23.3%) and 7.7% (95% CI 0.2-36.0%) from first and retreatment episodes 
respectively had isoniazid resistance, compared with 6.0% (95% CI 3.1-10.2%) and 
18.7% (95% CI 10.6-29.3%) in control clusters and 11.8% (95% CI 8.2 – 16.3%) among 
first TB episodes in the laboratory substudy.  
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Conclusions 
Tuberculosis after recent IPT has prevalence of drug resistance similar to background 
and treatment outcomes typical of this setting. These data support wider implementation 
of IPT. 
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INTRODUCTION 
Despite World Health Organization recommendations [1] and strong evidence of 
effectiveness [1-3], implementation of isoniazid preventive therapy (IPT) to reduce HIV-
associated tuberculosis has been limited. Reasons include concerns about promoting 
drug resistance, although there is little evidence that this occurs [5].  
 
Tuberculosis incidence in South Africa was estimated at 948/100,000 in 2007 [6] and is 
higher still among miners, partly due to high prevalence of HIV (estimated at 29%) [7] 
and silicosis [8]. The prevalence of latent tuberculosis infection among gold miners was 
recently estimated at 89% [9]. We are conducting a cluster-randomised trial ("Thibela 
TB") of community-wide IPT among gold miners in South Africa. The aim of this analysis 
was to describe characteristics of tuberculosis disease in individuals previously exposed 
to IPT in this trial.  
 
METHODS   
Setting  
Mining companies provide employees with free, on-site comprehensive health care, 
including tuberculosis and HIV services. In the Thibela TB study, clusters (all employees 
at a single or group of mine shafts) were randomised to control (routine tuberculosis 
control, including annual case finding by chest radiograph and targeted IPT offered to 
individuals with HIV or silicosis) or intervention (routine tuberculosis control as above 
plus the study intervention, i.e. tuberculosis screening and IPT offered to all employees 
without a specific contraindication, regardless of perceived tuberculosis risk or HIV 
status) arms. In intervention clusters, screening for active tuberculosis and other 
contraindications is by symptom questionnaire and chest radiograph [7, 10, 11]. Eligible 
participants are dispensed isoniazid 300mg and pyridoxine 25mg daily, self-
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administered, for 30 days initially and nine months in total, with monthly review by 
nurses at workplace-based study clinics for tuberculosis symptoms and adverse events.   
 
Study population and case ascertainment 
Individuals were included in this case series ("TB after IPT" group) if they were 
dispensed IPT at one of eight intervention clusters (starting July 2006), attended at least 
one follow up visit and subsequently started tuberculosis treatment (up to 16th February 
2009). Cases were identified through surveillance of incident tuberculosis as part of 
Thibela TB, through a concurrent mycobacterial culture substudy and through review of 
clinical records for individuals stopping IPT early. We included all those treated for 
tuberculosis, who attended at least one follow up visit (to be reasonably sure that some 
isoniazid had been taken), unless an outcome of “not TB” was recorded or only non-
tuberculous mycobacteria were isolated from sputum.  
 
Definitions 
Sites of disease, episode type, treatment regimens and outcomes (standard WHO 
definitions [12]) were abstracted from tuberculosis treatment records. We estimated the 
maximum duration of IPT using the number of monthly dispensing visits. Participants 
stopping IPT before nine months were assumed to have taken medication for 15/30 days 
preceding their final visit.  
 
Comparison groups 
To provide comparisons for the proportion with drug resistance in the TB after IPT group, 
we used two data sources: 
a) "control clusters": Tuberculosis case ascertainment in the seven control clusters was 
identical to that in intervention clusters. All tuberculosis cases with available drug 
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susceptibility data from two large control clusters were included in this comparison 
group.  
b) "laboratory substudy": Sputa from individuals presenting to clinics with symptoms but 
no prior history of tuberculosis underwent culture and drug susceptibility testing [13]. All 
tuberculosis cases in the laboratory substudy at any control cluster were included. 
 
The TB after IPT group included those who had not yet completed treatment, in order to 
avoid excluding those with longer treatment duration; i.e. retreatment cases or drug-
resistant tuberculosis. This was not possible in the control cluster comparison group as 
laboratory data are not abstracted until the end of treatment. In the laboratory substudy 
this was not an issue, as specimens were collected at the time of investigation for 
tuberculosis and thus drug susceptibility data were available in real time. 
 
Statistical methods 
Data analysis using STATA v.10 (Stata Corporation, College Station, Texas), included 
95% confidence intervals (CI) (binomial exact method) for proportions of isolates with 
drug resistance.   
 
Ethical considerations 
"Thibela TB" was approved by Research Ethics Committees of the University of 
KwaZulu Natal and the London School of Hygiene and Tropical Medicine. 
 
RESULTS 
126 individuals fulfilled inclusion criteria for the TB after IPT group, from a total of 23,095 
individuals starting IPT in Thibela TB up to 16th February 2009. Median age was 43 
(interquartile range [IQR] 38, 47) years and 125 (99%) were male; consistent with 
7 
 
 
workforce demographics. In control clusters, 11/275 (4%) individuals had evidence from 
medical records of ever having had IPT. 
 
Description of the TB after IPT group 
77/126 sputum samples cultured Mycobacterium tuberculosis; 42 were culture-negative 
and seven had no culture results available. The median estimated duration of IPT was 
105 days (IQR 45, 195), with 28/126 (22%) of this group completing all 270 days. The 
median time from starting IPT to starting tuberculosis treatment was 316 days (IQR 174, 
491) and 53/126 (42%) started tuberculosis treatment within the planned 270 days IPT.  
 
89/103 (86%) with known status were HIV positive. Median CD4 cell count was 196 
cells/mm3 (IQR 81, 296) (n=51). 21/89 (24%) HIV-positive individuals were known to be 
taking antiretroviral therapy at the start of tuberculosis treatment.  
94/126 (74.6%) were first tuberculosis episodes and 87/126 (69.0%) pulmonary. 43 
(34.1%) were smear and culture positive and 11 (8.7%) smear positive but culture 
negative. 
 
Treatment outcomes 
In 18/126, treatment was ongoing at the time of data collection and outcome not yet 
recorded. Among the remaining 108/126, 64/108 (59.3%) had documented cure or 
treatment completion, 33 (30.6%) were transferred out or had unknown outcome, 2/108 
had treatment failure or interruption. There were nine deaths (8.3%), four within the first 
two months of tuberculosis treatment; all eight with known status were HIV-positive; 
median CD4 count 124 cells/mm3 (n=6). Five of the deaths had culture-positive M. 
tuberculosis and all four cases with susceptibility results were susceptible to isoniazid 
and rifampicin.  
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Drug susceptibility: TB after IPT and comparison groups 
Of 77 M. tuberculosis isolates in the TB after IPT group, 71 (92.2%) had susceptibility 
testing results for isoniazid and rifampicin. None of the five with concurrent non-
tuberculous mycobacterial isolates had susceptibility data. In control clusters, of 319 M. 
tuberculosis isolates, 275 (86.2%) had susceptibility test results for isoniazid and 
rifampicin (table).  
 
Among first tuberculosis episodes, 7/58 (12.1%; 95%CI 5.0-23.3%) were resistant to 
isoniazid in the TB after IPT group, compared with 12/200 (6.0%; 95%CI 3.1-10.2%) in 
the control clusters and 32/270 (11.8%; 95%CI 8.2 – 16.3%) in the laboratory substudy 
(figure). For retreatment episodes, isoniazid resistance occurred in 1/13 (7.7%; 95%CI 
0.2-36.0) in the TB after IPT group and 14/75 (18.7; 95%CI 10.6 – 29.3) in control 
clusters.  
 
Tuberculosis screening failures in the TB after IPT group      
Four individuals most likely had tuberculosis that was missed at screening before IPT. 
Two were culture positive with fully susceptible M. tuberculosis from specimens taken 
due to abnormal chest radiographs, but IPT was dispensed in error: they were started on 
first-line treatment 9 and 184 days after starting IPT, and outcomes were transfer out 
and cure, respectively. The individual starting treatment after 184 days had taken an 
estimated 45 days of IPT and a later sputum specimen grew isoniazid-resistant M. 
tuberculosis. The other two had negative tuberculosis screens at the Thibela TB study 
site and were smear and culture negative on specimens taken later by mine health 
services, who initiated treatment based on results of occupational screening radiographs 
after 11 and 14 days of IPT. Both were documented to have completed treatment. 
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DISCUSSION 
Concern about generating isoniazid resistance is a major obstacle to wider 
implementation of IPT. These data do not support this concern. Treatment outcomes 
were typical of this setting, taking into account the high numbers of transfers to other 
treatment programmes and unrecorded outcomes. South Africa as a whole has not yet 
met the WHO targets for treatment outcomes [6]. Drug resistance was not more 
prevalent than in comparison groups. Among first episodes of tuberculosis, the 
prevalence of isoniazid resistance, at 12.1%, was higher in the TB after IPT than in 
control clusters (6.0%), but similar to that in the laboratory substudy (11.8%). In 
retreatment cases isoniazid resistance was less common in the TB after IPT group than 
control clusters (7.7 vs. 18.7%). The prevalence of isoniazid resistance among the TB 
after IPT group is also in keeping with a drug-resistance survey among gold miners in 
this area in the 1990s, in which 7.3% (95% CI 6.1 – 8.7) of first tuberculosis episodes 
and 14.3% (11.3 – 17.9) of retreatment episodes had isoniazid resistance [14]. In this 
analysis we present several comparators, acknowledging that each has limitations. 
Overall, although numbers of resistant cases were small and confidence intervals 
accordingly wide, the data do not suggest an increase in proportion of isoniazid-resistant 
cases among those exposed to tuberculosis screening and IPT. 
 
Treatment of latent tuberculosis should not, theoretically, promote anti-tuberculous drug 
resistance, as in latent infection the probability of selecting for a spontaneously-occurring 
isoniazid-resistant organism is remote, as organism numbers are low and bacterial 
division slow [15]. In a population of individuals with latent tuberculosis exposed to IPT, a 
higher prevalence of isoniazid resistance among subsequent tuberculosis cases would 
be expected even if IPT use did not itself generate resistance, as IPT is assumed to be 
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more effective in treating isoniazid-susceptible than isoniazid-resistant latent 
tuberculosis.  
 
We reported on tuberculosis episodes occurring during or relatively early after 
completing IPT. Given the high prevalence of HIV and tuberculosis in this population, the 
majority of tuberculosis cases are likely to have been due to recent infection [16].  
However, this relatively short follow up inevitably biases towards cases identified during 
IPT, who are those most likely to have been screening failures, to have received 
inadvertent monotherapy for active disease, and hence to have acquired isoniazid 
resistance. With longer follow up, we would expect an increasing proportion of cases to 
be due to re-infection after IPT. The control cluster comparison group may be biased 
towards a lower proportion with resistance, as drug susceptibility data are collected at 
the end of the treatment episode, thus potentially excluding individuals with longer 
treatment durations, due to previous treatment exposure or known baseline resistance. 
Effective screening before administering IPT is essential to avoid inadvertent isoniazid 
monotherapy for active tuberculosis. Overall consensus on the optimal screening 
method in resource-limited settings is yet to be reached.  
 
Three previous papers specifically describe active tuberculosis following IPT [17-19]. 
Methods differ and numbers are very small, so it is difficult to draw clear conclusions in 
terms of drug resistance from these studies. Data concerning tuberculosis after IPT from 
clinical trials have been reviewed previously in a meta-analysis [5]. The summary 
estimate for the risk of isoniazid resistance following IPT compared with those not 
exposed to IPT was 1.45 (95% CI 0.85-2.47), suggesting no evidence for an increase in 
resistance.  
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In conclusion, tuberculosis disease among mostly HIV-infected people previously 
exposed to IPT had treatment outcomes typical of this setting and a similar prevalence 
of isoniazid resistance to background. Concerns about generating drug-resistance 
should not impede implementation of IPT.  
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Table 1: Proportions of TB after IPT group and comparison groups with drug-resistant tuberculosis 
  TB after IPT group  
n=71 
 Thibela TB control clusters 
n=275 
 Laboratory substudy 
n=270 
Drug 
susceptibility 
 First episodes  
n=58 
%(95%CI) 
Retreatment 
episodes, n=13 
%(95%CI) 
 First episodes 
n=200 
%(95%CI) 
Retreatment 
episodes, 
n=75 
%(95%CI) 
 First  
episodes 
n=270 
%(95% CI) 
Susceptible to 
both isoniazid 
& rifampicin 
 51 
87.9%  
(76.7-95.0) 
11 
 84.6% (54.6-
98.1) 
 187 
93.5% 
 (89.1–96.5) 
60 
80.0%  
(69.2-88.4) 
 225/269
a 
87.7% 
(83.1-91.4%) 
Any isoniazid 
resistance
 
 7 
12.1%  
(5.0-23.3) 
1 
7.7%  
(0.2-36.0) 
 12 
6.0%  
(3.1-10.2) 
14 
18.7%  
(10.6-29.3) 
 32 
11.8% 
(8.2 – 16.3) 
Resistant to 
both isoniazid 
and rifampicin 
 1 
1.7%  
(0.0-9.2) 
1 
7.7%  
(0.2-36.0) 
 6 
3.0%  
(1.1-6.4) 
10 
13.3%  
(6.6-23.2) 
 21/269
a 
(7.8%) 
(4.9 – 11.7) 
a 
Drug susceptibility results for rifampicin were missing for one individual
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Figure 1: Percentages of TB episodes with any isoniazid resistance (Bars show 95% 
confidence intervals) 
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Retreatment  
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